Electra Therapeutics Closes IPO; Files Amended Certificate and Bylaws

What Happened

• Electra Therapeutics, Inc. announced it closed its initial public offering on September 21, 2026. The company sold 23,333,334 shares of common stock at $15.00 per share, generating approximately $350.0 million in aggregate gross proceeds before underwriting discounts, commissions and offering expenses.
• On the same date, the company filed an Amended and Restated Certificate of Incorporation with the Delaware Secretary of State and adopted Amended and Restated Bylaws. The board and stockholders had approved both documents to become effective upon the closing of the IPO.

Key Details

• IPO close date: September 21, 2026.
• Shares sold: 23,333,334 common shares at $15.00 per share.
• Aggregate gross proceeds: ~ $350.0 million (before fees and expenses).
• Corporate governance changes: filed Restated Certificate of Incorporation and adopted Restated Bylaws effective upon IPO closing.

Why It Matters

• The IPO provides Electra with a significant cash infusion that can fund operations, R&D, and growth plans; investors should note the stated figure is gross proceeds, not net proceeds after fees and expenses.
• The amended charter and bylaws formalize the company’s governance and capital structure as a public company; these changes can affect shareholder rights, board governance, and corporate procedures now that Electra is publicly listed.